logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5653.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5653.produseast1
Showing 1 - 5 of 5 Items
Showing 1 - 5 of 5 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Implementing a substance-use screening and intervention program for people living with rifampicin-resistant tuberculosis: pragmatic experience from Khayelitsha, South Africa

Reuter A, Beko B, Memani B, Furin J, Daniels J,  et al.
2022-01-31 • Tropical Medicine and Infectious Disease
2022-01-31 • Tropical Medicine and Infectious Disease
Substance use (SU) is associated with poor rifampicin-resistant tuberculosis (RR-TB) treatment outcomes. In 2017, a SBIRT (SU screening-brief intervention-referral to treatment) was inte...
Journal Article
|
Letter

A very sneaky bug: perspectives of front-line clinicians on whole-genome sequencing for drug-resistant TB

Memani B, Furin J, Cox HS, Reuter A
2022-12-01 • International Journal of Tuberculosis and Lung Disease
2022-12-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Letter

Pediatric delamanid treatment for children with rifampicin-resistant TB

Tyeku N, Apolisi I, Daniels J, Beko B, Memani B,  et al.
2022-10-01 • International Journal of Tuberculosis and Lung Disease
2022-10-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Commentary

Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa

Apolisi I, Mema N, Tyeku N, Beko B, Memani B,  et al.
2022-03-01 • Lancet Respiratory Medicine
2022-03-01 • Lancet Respiratory Medicine
Journal Article
|
Research

Causes of loss to follow-up from drug-resistant TB treatment in Khayelitsha, South Africa

Memani B, Beko B, Dumile N, Mohr-Holland E, Daniels J,  et al.
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
Patients initiated on drug-resistant TB (DR-TB) treatment in 2019 in Khayelitsha, South Africa, with a loss to follow-up outcome were evaluated to better understand reasons for loss to f...